

Serial No.: 10/051,662

Our File No. 31140-B

AMENDMENTS AND STATUS OF CLAIMS

As shown below, please withdraw claims 77, 85, 86, 88, 91-111, 126, 140-141, 146 and 148. Please amend claims 112, 114, 115, 123, 127 and 147 as shown below:

Claims 1-74 (canceled).

75. (Previously presented) A pharmaceutical product that is contraceptively effective comprising 28 daily sequential dosages, said product including 21 sequential daily hormone dosages, with each hormone dosage comprising a progestin product and an estrogen product and with at least one of said hormone dosages further comprising a Vitamin D compound, and said product further including 7 other daily dosages that do not contain either estrogen and/or progestin.

76. (Previously presented) The product of claim 75 wherein the Vitamin D compound is 1,25 (OH)₂ Vitamin D₃ (calcitriol).

77. (Previously presented) The product of claim 75 wherein the Vitamin D compound is Vitamin D₃ (cholecalciferol).

78. (Previously presented) The product of claim 75 wherein said the estrogen product is ethinyl estradiol.

79. (Previously presented) The product of claim 78 wherein the daily dosage of said ethinyl estradiol is less than or equal to 0.050 mg and greater than or equal to 0.020 mg.

80. (Previously presented) The product of claim 75 wherein the dosage of said Vitamin D compound in at least one of said hormone dosages is equivalent to at least 400 I.U.

81. (Previously presented) The product of claim 80 wherein the dosage of said Vitamin D compound in at least one of said hormone dosages is equivalent to at least 2000 I.U.

Serial No.: 10/051,662**Our File No. 31140-B**

82. (Previously presented) The product of claim 81 wherein the dosage of said Vitamin D compound in at least one of said hormone dosages is equivalent to at least 4000 I.U.

83. (Previously presented) The product of claim 75 wherein said product is adapted for daily administration of said Vitamin D compound with each said daily hormone dosage.

84. (Previously presented) The product of claim 75 wherein said product is adapted for administration of said Vitamin D compound on a less frequently than daily basis.

85. (Withdrawn) The product of claim 75 wherein said progestin product is a gonane.

86. (Withdrawn) The product of claim 75 wherein said progestin product is a pregnane.

87. (Previously presented) The product of claim 75 wherein said progestin product is a estrane.

88. (Withdrawn) The product of claim 75 wherein said progestin product is norgestimate.

89. (Previously presented) The product of claim 88 wherein said the estrogen product is ethinyl estradiol and the daily dosage of said ethinyl estradiol is less than or equal to 0.035 mg and greater than or equal to 0.020 mg.

90. (Previously presented) The product of claim 75 wherein at least one Vitamin D compound is in a single unit dosage with one dosage of said progestin product.

91. (Withdrawn) A pharmaceutical composition comprising a progestin product and a Vitamin D compound that does not have hydroxylation at both the 1 and 25 positions.

92. (Withdrawn) The composition of claim 91 wherein said progestin product and said Vitamin D compound are combined in a single unit dosage.

Serial No.: 10/051,662**Our File No. 31140-B**

93. (Withdrawn) The composition of claim 91 wherein the daily dosage equivalent of said progestin product is less than or equal to 10 mg of norethindrone.

94. (Withdrawn) The composition of claim 91 wherein the daily dosage equivalent of said progestin product is less than 1.25 mg of norethindrone.

95. (Withdrawn) The composition of claim 91 wherein said Vitamin D compound is Vitamin D₂ (ergocalciferol)

96. (Withdrawn) The composition of claim 95 wherein the Vitamin D compound is Vitamin D₃ (cholecalciferol).

97. (Withdrawn) The composition of claim 91 wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.

98. (Withdrawn) The composition of claim 91 wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.

99. (Withdrawn) The composition of claim 91 wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.

100. (Withdrawn) The composition of claim 95 wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.

101. (Withdrawn) The composition of claim 95 wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.

102. (Withdrawn) The composition of claim 95 wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.

103. (Withdrawn) The composition of claim 96 wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.

Serial No.: 10/051,662**Our File No. 31140-B**

104. (Withdrawn) The composition of claim 96 wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.

105. (Withdrawn) The composition of claim 96 wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.

106. (Withdrawn) The composition of claim 91 wherein said progestin product is a gonane.

107. (Withdrawn) The composition of claim 91 where said composition further comprises an estrogen product.

108. (Withdrawn) The composition of claim 91 where the estrogen is ethinyl estradiol.

109. (Withdrawn) The composition of claim 108 wherein the dosage of said ethinyl estradiol is less than or equal to 0.035 mg and greater than or equal to 0.020 mg.

110. (Withdrawn) The composition of claim 91 wherein said progestin product is progesterone.

111. (Withdrawn) The composition of claim 91 wherein said progestin product is pregnane.

112. (Currently amended) A pharmaceutical composition comprising a Vitamin D compound and a ~~gonane~~ progestin product wherein the dosage of said progestin product is less than or equal to an equivalent of 2.5 mg of norethindrone.

113. (Previously presented) The composition of claim 112 wherein said progestin product and said Vitamin D compound are combined in a single unit dosage.

114. (Currently amended) The composition of claim 112 wherein ~~the daily dosage equivalent of said progestin product is less than or equal to 10 mg of norethindrone.~~

Serial No.: 10/051,662**Our File No. 31140-B**

115. (Currently amended) The composition of claim 112 wherein the [[daily]] dosage equivalent of said progestin product is less than 1.25 mg of norethindrone.

116. (Previously presented) The composition of claim 112 wherein the Vitamin D compound is calcitriol.

117. (Previously presented) The composition of claim 112 wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.

118. (Previously presented) The composition of claim 112 wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.

119. (Previously presented) The composition of claim 112 wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.

120. (Previously presented) The composition of claim 117 where said composition further comprises an estrogen product.

121. (Previously presented) The composition of claim 120 where the estrogen is ethinyl estradiol.

122. (Previously presented) The composition of claim 121 wherein the dosage of said ethinyl estradiol is less than or equal to 0.035 mg and greater than or equal to 0.020 mg.

123. (Currently amended) The composition of claim [114] 122 wherein said progestin product is norethindrone ~~norgestimate~~.

124. (Withdrawn) The composition of claim 114 wherein said progestin product is levonorgestrel.

125. (Previously presented) A pharmaceutical product comprising 21 sequential daily dosages, said 21 daily dosages comprising a progestin product and/or an estrogen product, with

Serial No.: 10/051,662**Our File No. 31140-B**

at least one of said daily dosages further comprising a Vitamin D compound that does not have hydroxylation at both the 1 and 25 positions.

126. (Withdrawn) The product of claim 125 wherein said Vitamin D compound is Vitamin D₂ (ergocalciferol).

127. (Currently amended) The product of claim 126 wherein the Vitamin D compound is 1,25 (OH)₂ Vitamin D₃ (calcitriol cholecalciferol).

128. (Previously presented) The product of claim 127 wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.

129. (Previously presented) The product of claim 125 wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.

130. (Previously presented) The product of claim 125 wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.

131. (Previously presented) The product of claim 125 wherein said product is adapted for daily administration of said Vitamin D compound with each daily hormone dosage.

132. (Previously presented) The product of claim 125 wherein said product is adapted for administration of said Vitamin D compound on a less frequently than daily basis.

133. (Previously presented) The product of claim 125 wherein said estrogen product is conjugated equine estrogen.

134. (Previously presented) The product of claim 128 wherein the dosage of said conjugated equine estrogen 0.625 mg.

135 (Previously presented) The product of claim 125 wherein said estrogen product is estradiol.

Serial No.: 10/051,662**Our File No. 31140-B**

136. (Previously presented) The product of claim 125 wherein the daily dosage equivalent of said progestin product is less than or equal to 10 mg of norethindrone.

137. (Previously presented) The product of claim 125 wherein the daily dosage equivalent of said progestin product is less than or equal to 2.5 mg of medroxyprogesterone acetate daily.

138. (Previously presented) The product of claim 125 wherein said Vitamin D compound is in a single unit dosage with said progestin product and/or estrogen product.

139. (Previously presented) A pharmaceutical product comprising 21 sequential daily dosages, said 21 daily dosages comprising a progestin product and/or an estrogen product, with at least one of said daily dosages further comprising a Vitamin D compound, and wherein said product is adapted for administration of said Vitamin D compound on a less frequently than daily basis.

140. (Withdrawn) The product of claim 134 wherein said Vitamin D compound is Vitamin D₂ (ergocalciferol).

141. (Withdrawn) The product of claim 134 wherein the Vitamin D compound is Vitamin D₃ (cholecalciferol).

142. (Previously presented) The product of claim 134 wherein said Vitamin D compound is calcitriol.

143. (Previously presented) The product of claim 134 wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.

144. (Previously presented) The product of claim 134 wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.

Serial No.: 10/051,662**Our File No. 31140-B**

145. (Previously presented) The product of claim 134 wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.

146. (Withdrawn) The product of claim 134 wherein said progestin product is a gonane.

147. (Currently amended) The product of claim 134 wherein said progestin product is an estrane a pregnane.

148. (Withdrawn) The product of claim 134 wherein said progestin product is a progesterone

149. (Previously presented) The product of claim 134 wherein said the estrogen product is conjugated equine estrogen.

150. (Previously presented) The product of claim 134 wherein the dosage of said conjugated equine estrogen is 0.625 mg.

151. (Previously presented) The product of claim 134 wherein said estrogen product is estradiol.

152. (Previously presented) The product of claim 134 wherein the daily dosage equivalent of said progestin product is less than or equal to 10 mg of norethindrone.

153. (Previously presented) The product of claim 134 wherein the daily dosage equivalent of said progestin product is less than or equal to 2.5 mg of medroxyprogesterone acetate daily.